White Paper: Potential Savings from Accelerating U.S. Approval of Complex Generics

by Alex Brill, Founder and CEO, Matrix Global Advisors; Resident Fellow, American Enterprise Institute

Accelerating FDA approval for complex generic drugs is an untapped avenue for improving access to low-cost drugs for patients and saving the U.S. billions per year. According to an independent analysis commissioned by Teva Pharmaceuticals, regulatory delays for complex generics cost the U.S. health system an estimated $1.3 billion each year. Complex drugs, which include epinephrine auto-injectors and inhalers used to treat asthma, are critical to the care of conditions such as metastatic breast cancer, osteoporosis and diabetes.

Download White Paper


The HIll: Complex Generics & the Prescription Landscape

View the event "Complex Generics & the Prescription Landscape" hosted by The Hill, where Alex Brill along with leading medical voices, policy experts and members of Congress discussed how complex generic medical alternatives could impact and enhance the American health care system.

View Event



Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.